Bortezomib for Myeloma — Much Ado about Something
- 16 June 2005
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (24) , 2546-2548
Abstract
Multiple myeloma is a neoplastic plasma-cell dyscrasia that will cause more than 11,000 deaths in 2005 in the United States alone.1 The usefulness of the many therapies for multiple myeloma is limited, and virtually all patients eventually die from the disease. When thalidomide was shown to be effective against relapsed myeloma in 1999,2 more than 30 years had elapsed since a clinical response to any single agent had been reported in at least 25 percent of treated patients.35 By the early 2000s, it had become clear that another two agents — lenolidomide6 and bortezomib7 — had activity against malignant . . .Keywords
This publication has 11 references indexed in Scilit:
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003
- Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2002
- Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed MyelomaJournal of Clinical Oncology, 2002
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- High‐dose dexamethasone for refractory or relapsing multiple myelomaAmerican Journal of Hematology, 1991
- High-Dose Glucocorticoid Treatment of Resistant MyelomaAnnals of Internal Medicine, 1986
- Multiple MyelomaJAMA, 1964